Inhibitor Therapeutics (INTI) Interest Expenses (2012 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Interest Expenses came in at $200000.0 in Q1 2026, up 1900.0% YoY from $10000.0 in Q1 2025, and up 1813.51% on a QoQ basis from $10452.0 in Q4 2025.
Inhibitor Therapeutics (INTI) Interest Expenses (2012 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 14 years of Interest Expenses data on file, last reported at $200000.0 in Q1 2026.
- Quarterly Interest Expenses rose 1900.0% year-over-year to $200000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200000.0 (up 1900.0% YoY) and the FY2025 annual result came in at $28743.0, down 13.33% from the prior year.
- Interest Expenses rose to $200000.0 in Q1 2026, from $10452.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $200000.0 in Q1 2026 to a low of $3356.0 in Q4 2022.
- A 5-year average of $42099.2 and a median of $20226.0 in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses soared 2690.02% — and 2025, when it plunged 90.0%.
- Tracing INTI's Interest Expenses over 5 years: stood at $3356.0 in 2022, then soared by 2690.02% to $93633.0 in 2023, then slumped by 64.58% to $33164.0 in 2024, then plunged by 68.48% to $10452.0 in 2025, then jumped by 1813.51% to $200000.0 in 2026.
- The last three Interest Expenses figures came in at $200000.0 (Q1 2026), $10452.0 (Q4 2025), and $10000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200,000.00 |
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 10,452.00 |
| Dec 31, 2025 | 10,452.00 |
| Sep 30, 2025 | 10,000.00 |
| Sep 30, 2025 | 10,000.00 |
| Jun 30, 2025 | 33,104.00 |
| Jun 30, 2025 | 33,104.00 |
| Mar 31, 2025 | 10,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 33,164.00 |
| Dec 31, 2024 | 33,164.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 70,000.00 |
| Jun 30, 2024 | 70,000.00 |
| Mar 31, 2024 | 50,000.00 |
| Mar 31, 2024 | 50,000.00 |
| Dec 31, 2023 | 93,633.00 |
| Dec 31, 2023 | 93,633.00 |